Sheffield scientists contributed to the foundation of the landmark Canakinumab (CANTOS) trial
The classical innate immune cytokine interleukin-1 beta is abundant in human diseased coronary arteries, especially in endothelium and in microvessels in the outer layers of arteries, and increases as disease worsens.
In the new study, sponsored by Novartis, patients who received an injection of an antibody to block interleukin-1 beta had significantly reduced excess inflammation and there were fewer deaths from heart attacks and strokes. There were also reductions in arthritis-related conditions and deaths from cancers.
Sheffield researchers past and present working on IL-1 beta have always believed in its primacy in controlling important physiological and disease causing processes. Now, the challenge is to decide which patients need this treatment (and similar ones) and when.
NEJM DOI: 10.1056/NEJMoa1707914
The University’s four flagship institutes bring together our key strengths to tackle global issues, turning interdisciplinary and translational research into real-world solutions.